Aurealis Therapeutics, a private biopharmaceutical company developing novel three-in-one combination biologics for chronic non-healing wounds, cancer and osteoarthritis announced today that CEO Juha Yrjänheikki will attend and present the company’s progress at the 11th Annual European Life Sciences CEO Forum & Exhibition in Zurich on February 26-27th 2018.
The presentation is scheduled for Monday, February 26th 2018 at 11:50 am. Hilton Zurich Airport Hotel, Room Berne, Presentation Track A.
“We are excited to attend and speak to investors and pharma of our diabetic and vascular foot ulcer product AUP-16, which is in preparation for clinical trial submission to start our first-in-human study in patients this year. AUP-16 is the first ever three-in-one multitherapy option for chronic wound sufferers” stated CEO Yrjänheikki.
“Reaching clinical stage with our lead product AUP-16 has given us and our investors a lot of confidence. After an era of single molecule entity failures, the leading wound care clinical opinion leaders share our view on AUP-16 as a potential game-changer that hits all the key points for the patients with chronic wounds – anti-inflammation, angiogenesis induction and granulation tissue promotion” continued CMO Dirk Weber, MD, PhD.
AUP-16 is the lead product from Aurealis Therapeutics “combination biologics in one product” technology platform. It is a genetically engineered Lactococcus lactis, a non-pathogenic, probiotic bacteria, expressing human basic fibroblast growth factor (FGF2, bFGF), interleukin-4 (IL-4) and macrophage colony stimulating factor (CSF-1, mCSF) – all in one product and accepted as one active pharmaceutical ingredient from regulatory perspective.
AUP-16 is topically applied on chronic wounds and covered by wound dressing (e.g. in diabetic foot ulcers, venous leg ulcers and pressure ulcers). In the wound AUP-16 acts as millions of bioreactors producing the therapeutic proteins, which are designed to i) halt chronic inflammation in the wound, ii) induce growth of new blood vessels, and iii) promote granulation tissue formation and skin re-epithelization – all in one product.
AUP-16 is at clinical trial application submission stage in Europe. It is produced and scaled-up at GMP level with low cost-of-goods, has passed GLP safety and toxicity studies, and is planned to enter phase 1 clinical trial in 2018. It has passed EU regulatory authority scientific advice and is showing superior efficacy in non-clinical efficacy studies in non-healing diabetic wounds.
About the 11th Annual European Life Sciences CEO Forum & Exhibition
Back for its 11th Annual edition, this global bio-pharma industry forum addresses through its conference program the main challenges for 2018 in investment, partnering and alliance management. Key players contribute their insights in panels which cover the macro picture as well as innovation in the different therapeutic sectors. The Forum also features keynote speeches by KOL, about 60 selected corporate presentations from established (public and private) and emerging biotechs seeking to promote investment and partnering opportunities. There is also a focus on early stage innovation and an elevator session with up 20 presentations by start-ups from BioMed and Digital Health.
About Aurealis Therapeutics
Aurealis Therapeutics AG is a Swiss-Finnish private clinical-stage biopharmaceutical company focusing on the development of the clinical asset AUP-1602, the first-in-class four-in-one combination biologic drug for chronic wounds and other chronic inflammatory and degenerative diseases. The product is based on proprietary technology where genetically engineered lactic acid bacteria act as millions of small immune activating bioreactors in the human tissue and produce multiple human therapeutic proteins into the target tissue to effectively and safely re-educate the distorted host immune microenvironment to a proper state.
For more information:
Juha Yrjänheikki, CEO
Tel: +358 45 8433550
Email: juha(at)aurealistherapeutics.com
